Article

Efficacy of Osimertinib Plus Bevacizumab In Glioblastoma Patients With Simultaneous EGFR Amplification And EGFRvIII Mutation

2021-07-27

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Amplification of <italic>EGFR </italic>and its active mutant <italic>EGFRvIII</italic> are common in glioblastoma (GB). While <italic>EGFR</italic> and <italic>EGFRvIII</italic> play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has shown limited efficacy. To improve the likelihood of effectiveness, we...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6825bc35-e63c-5937-a380-e5b44acc494e
DOI: 10.21203/rs.3.rs-698468/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy of Osimertinib Plus Bevacizumab In Glioblastoma Patients With Simultaneous EGFR Amplification And EGFRvIII MutationDOI 10.21203/rs.3.rs-698468/v1Read

Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.Semantic proximity Read

Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.Semantic proximity Read

Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors.Semantic proximity Read

EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.Semantic proximity Read

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.Semantic proximity Read

EGFR as a clinical marker in glioblastomas and other gliomas.Semantic proximity Read

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.Semantic proximity Read

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysisSemantic proximity Read

Updated Insights on EGFR Signaling Pathways in GliomaSemantic proximity Read

Management of Asynchronous Multifocal Adult Glioblastoma with Loss of BRAFV600E-Mutant Clonality: A Case ReportSemantic proximity Read

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma.Semantic proximity Read

EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.Semantic proximity Read